Furthermore, as lumican modulates the response to the matrix-targeting therapy peptide TAX inhibiting tumor growth, it presents a feasible therapeutic option for neuroblastoma [68].Indeed, the attenuation of the FOXO3/LUM axis by the small molecular weight compound repaglinide is suggested as a novel strategy for neuroblastoma and other FOXO3-dependent neoplasms [62]. The gene discussed is FOXO3; the disease is neoplasm.